2008
The Role of ICOS in Peripheral Inflammation in Lupus
Eardley L, Odegard J, Craft J. The Role of ICOS in Peripheral Inflammation in Lupus. The FASEB Journal 2008, 22: 668.18-668.18. DOI: 10.1096/fasebj.22.1_supplement.668.18.Peer-Reviewed Original ResearchCostimulatory molecule ICOST cellsPeripheral inflammationDendritic cellsChemokine receptorsMRL/Faslpr miceExpression of CCR6Role of ICOSChemokine receptor expressionMajority of CD4Role of CD4Lupus-prone miceSevere renal diseaseFaslpr miceIndependent cytokinesLupus nephritisEffector cytokinesIL-10Lupus miceRenal diseaseCellular infiltrateChemokine productionSuch inflammationIL-5Certain chemokines
2007
CNS lupus in MRL/Faslpr mice (130.15)
Choi J, Chahboune H, Hyder F, Craft J. CNS lupus in MRL/Faslpr mice (130.15). The Journal Of Immunology 2007, 178: s230-s230. DOI: 10.4049/jimmunol.178.supp.130.15.Peer-Reviewed Original ResearchMRL/Faslpr miceFaslpr miceDiffusion tensor imagingControl miceStructural abnormalitiesCentral nervous system injurySpontaneous autoimmune diseaseLupus-prone miceNervous system injuryToll-like receptorsWeeks of ageCNS lupusIg depositionNeurological deficitsHuman SLENeuropsychiatric involvementSystem injuryAntibody depositionAutoimmune diseasesDTI alterationsMRL miceChoroid plexusMiceTensor imagingHippocampus
2006
Abrogation of skin disease in LUPUS‐prone MRL/FASlpr mice by means of a novel tylophorine analog
Choi J, Gao W, Odegard J, Shiah H, Kashgarian M, McNiff JM, Baker DC, Cheng Y, Craft J. Abrogation of skin disease in LUPUS‐prone MRL/FASlpr mice by means of a novel tylophorine analog. Arthritis & Rheumatism 2006, 54: 3277-3283. PMID: 17009262, DOI: 10.1002/art.22119.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusEnd-organ diseaseInflammatory skin diseaseMRL/Skin diseasesMRL/Faslpr miceFemale MRL/NF-kappaB inhibitorFlow cytometric analysisFaslpr miceAutoantibody titersIgG levelsLupus erythematosusLymph nodesRenal diseaseVehicle treatmentKidney diseaseHepatic toxicityTotal IgMTylophorine analogsAntichromatin autoantibodiesTherapeutic effectHistopathologic analysisMurine modelSignificant abrogation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply